BridgeBio Pharma, Inc. (BBIO)

Every figure this model derived for BBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,015,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 720,160,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,093,138,000 AssetsCurrent 2026-06-30
current liabilities 890,648,000 LiabilitiesCurrent 2026-06-30
equity -2,515,215,000 StockholdersEquity 2026-06-30
interest expense 49,595,000 InterestExpenseNonoperating 2026-06-30
ocf -434,374,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 713,069,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 147,215,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BBIO on one particular measure came for.

RatioValue
cash operating margin-48.45
current ratio1.24
current ratio reported1.23
deferred revenue growth-30.19
dilution pct2.93
fcf margin-61.06
growth cv1.43
interest cover-10.04
operating margin-69.81
owner earnings margin-81.7
revenue growth202.39
revenue growth per share193.78
rule of 40132.58
sbc pct revenue20.65

What to be careful about

What this model itself distrusts about BBIO's figures. Written by the derivation as it ran, not added afterwards.